Söndag 11 Maj | 18:05:59 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2025-06-26 08:50 Bokslutskommuniké 2025
2025-03-13 - Kvartalsrapport 2025-Q3
2025-01-08 - Extra Bolagsstämma 2025
2024-11-28 - Kvartalsrapport 2025-Q2
2024-10-12 - X-dag ordinarie utdelning PHI 0.00 SEK
2024-09-16 - Kvartalsrapport 2025-Q1
2024-06-26 - Bokslutskommuniké 2024
2024-03-27 - Kvartalsrapport 2024-Q3
2023-12-21 - Kvartalsrapport 2024-Q2
2023-11-15 - Extra Bolagsstämma 2024
2023-10-27 - Årsstämma
2023-10-13 - X-dag ordinarie utdelning PHI 0.00 SEK
2023-09-20 - Kvartalsrapport 2024-Q1
2023-06-23 - Bokslutskommuniké 2023
2023-05-09 - Extra Bolagsstämma 2023
2023-03-28 - Kvartalsrapport 2023-Q3
2022-12-21 - Kvartalsrapport 2023-Q2
2022-10-31 - Årsstämma
2022-10-14 - X-dag ordinarie utdelning PHI 0.00 SEK
2022-09-29 - Kvartalsrapport 2023-Q1
2022-06-29 - Bokslutskommuniké 2022
2022-03-21 - Kvartalsrapport 2022-Q3
2022-03-15 - Extra Bolagsstämma 2022
2021-12-29 - Kvartalsrapport 2022-Q2
2021-10-20 - Extra Bolagsstämma 2021
2021-10-11 - X-dag ordinarie utdelning PHI 0.00 SEK
2021-09-29 - Kvartalsrapport 2022-Q1
2021-06-24 - Bokslutskommuniké 2021
2021-03-16 - Kvartalsrapport 2021-Q3
2020-12-14 - Kvartalsrapport 2021-Q2
2020-10-20 - Årsstämma
2020-10-15 - X-dag ordinarie utdelning PHI 0.00 SEK
2020-09-28 - Kvartalsrapport 2021-Q1
2020-06-25 - Bokslutskommuniké 2020
2020-03-12 - Kvartalsrapport 2020-Q3
2019-12-17 - Kvartalsrapport 2020-Q2
2019-10-16 - X-dag ordinarie utdelning PHI 0.00 SEK
2019-10-15 - Årsstämma
2018-09-27 - X-dag ordinarie utdelning PHI 0.00 SEK
2018-09-26 - Årsstämma
2018-06-18 - Extra Bolagsstämma 2019
2018-06-12 - Bokslutskommuniké 2018
2018-03-12 - Kvartalsrapport 2018-Q3
2017-09-26 - X-dag ordinarie utdelning PHI 0.00 SEK
2017-09-25 - Årsstämma
2017-09-11 - Kvartalsrapport 2018-Q1
2017-06-19 - Bokslutskommuniké 2017
2017-03-13 - Kvartalsrapport 2017-Q3
2017-01-01 - Extra Bolagsstämma 2018
2016-11-30 - Kvartalsrapport 2017-Q2
2016-09-06 - X-dag ordinarie utdelning PHI 0.00 SEK
2016-09-05 - Årsstämma
2016-09-05 - Kvartalsrapport 2017-Q1
2016-06-13 - Bokslutskommuniké 2016
2016-02-22 - Kvartalsrapport 2016-Q3
2016-02-16 - Extra Bolagsstämma 2017
2015-11-30 - Kvartalsrapport 2016-Q2
2015-09-08 - X-dag ordinarie utdelning PHI 0.00 SEK
2015-09-07 - Årsstämma
2015-09-07 - Kvartalsrapport 2016-Q1
2015-06-16 - Bokslutskommuniké 2015
2015-03-16 - Kvartalsrapport 2015-Q3
2014-12-01 - Kvartalsrapport 2015-Q2
2014-10-07 - X-dag ordinarie utdelning PHI 0.00 SEK
2014-10-06 - Årsstämma
2014-10-06 - Kvartalsrapport 2015-Q1
2014-06-30 - Bokslutskommuniké 2014

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
PHI är verksamt inom medicinteknik och utvecklar både hårdvara och mjukvara för kvantitativ analys av levande cellkulturer. Produkterna HoloMonitor® bygger på icke-invasiv QPI-teknologi som insamlar data om cellkvalitet och säljs global via distributörer med fokus på preklinisk cancerforskning, stamcellerforskning och läkemedelsutveckling. Framöver fokuserar PHI på att utveckla sina produkter till den kliniska marknaden och inom regenerativ medicin. PHI har kontor i Lund, Boston, och Winston-Salem.
2023-04-11 14:27:41

Today is the first day of the exercise period for Phase Holographic Imaging PHI AB's ("PHI" or the "Company") warrants of series TO 3, which were issued in connection with the Company's rights issue of units that was announced on 22 February 2022. Holders of warrants of series TO 3 have, for each warrant, the right to subscribe for one (1) new share in PHI at a price of SEK 3.78 per share. The exercise period runs until and including 2 May 2023.

In connection with the Company's rights issue of units that was announced on 22 February 2022, PHI issued 3,365,405 warrants of series TO 3. Each warrant of series TO 3 entitles the holder to subscribe for one (1) new share in PHI at a price of SEK 3.78 per share during the exercise period that runs from 11 April 2023 until and including 2 May 2023.

At full utilization of warrants of series TO 3, the Company will be provided proceeds of approximately SEK 12.7 million before deduction of transaction related costs which are estimated to approximately SEK 0.65 million (corresponding to approximately 5 percent of the highest issue volume). With the net proceeds, it is the Company's intention to finance the following activities (in order of priority):
  • GLP/GAMP validation at and for biomanufacturing facilities
  • Market introduction Fluorescence unit
  • Develop within regenerative medicine

Upon full exercise of warrants of series TO 3, the number of shares in PHI will increase by 3,365,405 shares to a total of 23,818,105 shares and the share capital will increase by SEK 673,081.00 to SEK 4,763,621.00. The dilution at full utilization amounts to approximately 14 percent of the votes and capital.

More information about the Company and the offer is available on the websites of PHI (www.phiab.com), Sedermera Corporate Finance AB (www.sedermera.se) and Nordic Issuing AB (www.nordic-issuing.se). Complete terms and conditions for warrants of series TO 3 are available on the Company's website (www.phiab.com).

Important dates
  • 11 April 2023: The exercise period begins

  • 27 April 2023: Last day of trading in warrants

  • 2 May 2023: The exercise period ends

  • 4 May 2023: Planned communication of the outcome of the warrant exercise

  • 23 May 2023: Planned conversion of interim shares to ordinary shares

Here is how to exercise warrants of series TO 3

For warrants not to expire worthless, warrant holders must subscribe for new shares, with the support of warrants, at 17:00 CEST on 2 May 2023, at the latest, alternatively sell warrants no later than on 27 April 2023.

Warrants can be registered in two ways:

1. In a securities custody account with a bank or other nominee (for example, Avanza or Nordnet), in an investment savings account (Sw. Investeringssparkonto) or endowment account (Sw. Kapitalförsäk­ring). The warrants are then nominee registered.

2. In a VP-account (a VP-account starts with three zeros). The warrants are then directly registered.

If warrants are nominee registered

Subscription and payment of new shares, with the support of warrants, shall be made to the account-holding bank/nominee with which the warrants are registered. The subscription and payment shall be made in accordance with the instructions from each such bank or nominee. Usually, the bank/nominee sends out a digital notice to the account holder, otherwise it is usually enough to log into the securities custody account from the first day in the exercise period in order to get instructions on how to exercise warrants for subscription of new shares. The warrant holder is advised to contact its bank or trustee in the event that these instructions are not found. Please note that banks and other nominees may set different time limits for subscription, hence the warrant holder is recommended to contact the account-holding bank/nominee early in the exercise period to obtain information about subscription and payment. A letter will be sent out to most nominee registered warrant holders. Subscribed and paid for shares may be registered as "interim shares" or "IA" into your securities custody account until registration of the issue is completed with the Swedish Companies Registration Office, whereby interim shares will automatically be converted to ordinary shares in PHI.

If warrants are directly registered

No VP-account statement will be sent out. Subscription of new shares, with the support of warrants, shall be made by sending a completed subscription form to Nordic Issuing AB via e-mail. In connection with sending the completed subscription form to Nordic Issuing AB, payment must be made in accordance with the payment instructions stated on the subscription form. Subscription form will be available on Nordic Issuing's website (www.nordic-issuing.se).

Completed subscription form and payment must be registered with Nordic Issuing AB no later than 17:00 CEST on 2 May 2023. Subscribed and paid for shares will be registered as "interim shares" or "IA" into your VP-account until registration of the issue is completed with the Swedish Companies Registration Office, whereby interim shares will automatically be converted to ordinary shares in PHI.

Advisors

In connection with the exercise of warrants of series TO 3, Sedermera Corporate Finance AB is acting as financial advisor, Markets & Corporate Law Nordic AB as legal advisor and Nordic Issuing AB as issuing agent. Shark Communication AB is assisting the Company with advice regarding communication.

For more information about the warrants of series TO 3, please contact:

Sedermera Corporate Finance AB
Phone: +46 40 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se